NCT01031992View on ClinicalTrials.gov

Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

August 31, 2002

Study Completion Date

October 31, 2002

Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
DRUG

Tranexamic acid first, than placebo

For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.

DRUG

First placebo, than Tranexamic acid.

First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.

Trial Locations (1)

66421

Universitätskliniken des Saarlandes, HNO-Abteilung, Homburg

All Listed Sponsors
collaborator

Pharmacia GmbH, Erlangen, Germany

UNKNOWN

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

University Hospital, Saarland

OTHER

NCT01031992 - Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Biotech Hunter | Biotech Hunter